Article
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Annals of hematology - 1 Jul 2010
Koh Youngil, Kim Inho, Yoon Sung-Soo, Kim Byoung Kook, Kim Dae-Young, Lee Je-Hwan, Lee Kyoo-Hyung, Park Eunkyung, Kim Hyeoung-Joon, Sohn Sang Kyun, Joo Young Don, Kim Seok Jin, Chung Jooseop, Shin Ho-Jin, Kim Sung-Hyun, Kim Chul Soo, Song Hong Suk, Kim Min Kyoung, Hyun Myung Soo, Ahn Jin Seok, Jung Chul Won, Park Seonyang
Abstract excerpt
The aim of this phase IV study was to (1) to define efficacy of escalating dose imatinib in chronic myeloid leukemia (CML) patients showing suboptimal response to standard dose imatinib and (2) to find markers that predict the response to escalating doses of imatinib. CML patients in chronic phase (CP) who failed to achieve optimal response with 400 mg/day imatinib or patients in accelerated phase (AP) or blast...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.